Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-016053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-03 | 2023-03-01 | RARE | Bedrosian Camille L | EVP, Chief Medical Off | A - Grant | $0.00 | +2,663 | 50.6K | +6% | $0 | |
| 2023-03-03 | 2023-03-01 | RARE | Bedrosian Camille L | EVP, Chief Medical Off | S - Sale | $45.25 | -3,881 | 46.7K | -8% | -$175.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 2,663 | $0.00 | 50,601 | D | — | — | (F1) Represents shares of common stock into which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. |
| 2 | Common | Common Stock | 2023-03-01 | S | D | 3,881 | $45.25 | 46,720 | D | — | — | (F2) Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). (F3) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |